Tag: source

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ^® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ^®. IXCHIQ^® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Agricultural Adjuvants Market size & share revenue was valued at approximately USD 3.9 Billion in 2024 and is expected to reach USD 4.3 Billion in 2025 and is expected to reach around USD 6.2 Billion by 2034, at a CAGR of 4.78% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Clariant AG, Solvay SA, The Dow Chemical Company, Huntsman International LLC, Evonik Industries AG, Ingevity, Nufarm Limited, Corteva Agriscience, Croda International PLC, BASF SE, Miller Chemical & Fertilizer LLC., Helena Chemical Company, Winfield United, Wilbur-Ellis Holdings Inc., Stepan Company and others.

NEW ORLEANS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

VEON 2Q25 Earnings Release: Direct Digital Revenues Up 57% YoY. Solid Execution, Strong Results

New Nikon Z and Canon RF variants of Tamron's focal-range monster for APS-C cameras, the Tamron 18-300mm f/3.5-6.3 Di III-A2 VC VXD, are now available for pre-order.

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten public offering of 20,895,522 shares of its common stock at a price to the public of $3.35 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,492,537 shares of common stock at a price to the public of $3.3499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,358,208 shares of its common stock. The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about August 8, 2025, subject to satisfaction of customary closing conditions.